BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22834474)

  • 1. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome.
    Chamberlain SM; Rao SS
    Expert Opin Drug Saf; 2012 Sep; 11(5):841-50. PubMed ID: 22834474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Saad R; Chey WD
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):497-508. PubMed ID: 19072397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lubiprostone for constipation and irritable bowel syndrome with constipation.
    Tuteja AK; Rao SS
    Expert Rev Gastroenterol Hepatol; 2008 Dec; 2(6):727-33. PubMed ID: 19090733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lubiprostone for the treatment of opioid-induced bowel dysfunction.
    Wong BS; Camilleri M
    Expert Opin Pharmacother; 2011 Apr; 12(6):983-90. PubMed ID: 21385112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lubiprostone--a novel treatment for irritable bowel syndrome with constipation.
    Owen RT
    Drugs Today (Barc); 2008 Sep; 44(9):645-52. PubMed ID: 19137119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
    Raschi E; De Ponti F
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):293-305. PubMed ID: 24387275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lubiprostone: a chloride channel activator for treatment of chronic constipation.
    Ambizas EM; Ginzburg R
    Ann Pharmacother; 2007 Jun; 41(6):957-64. PubMed ID: 17519292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
    Lacy BE; Chey WD
    Expert Opin Pharmacother; 2009 Jan; 10(1):143-52. PubMed ID: 19236188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lubiprostone: chloride channel activator for chronic constipation.
    Rivkin A; Chagan L
    Clin Ther; 2006 Dec; 28(12):2008-21. PubMed ID: 17296458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation.
    Chey WD; Drossman DA; Johanson JF; Scott C; Panas RM; Ueno R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):587-99. PubMed ID: 22251419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
    Johanson JF; Drossman DA; Panas R; Wahle A; Ueno R
    Aliment Pharmacol Ther; 2008 Apr; 27(8):685-96. PubMed ID: 18248656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation.
    Crowell MD; Harris LA; DiBaise JK; Olden KW
    Curr Opin Investig Drugs; 2007 Jan; 8(1):66-70. PubMed ID: 17263187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lubiprostone: RU 0211, SPI 0211.
    Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.
    Schey R; Rao SS
    Dig Dis Sci; 2011 Jun; 56(6):1619-25. PubMed ID: 21523369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
    Ginzburg R; Ambizas EM
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1091-7. PubMed ID: 18680443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lubiprostone for the treatment of functional constipation in children.
    Hyman PE; Di Lorenzo C; Prestridge LL; Youssef NN; Ueno R
    J Pediatr Gastroenterol Nutr; 2014 Mar; 58(3):283-91. PubMed ID: 24048162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
    Johanson JF; Morton D; Geenen J; Ueno R
    Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
    Johanson JF; Ueno R
    Aliment Pharmacol Ther; 2007 Jun; 25(11):1351-61. PubMed ID: 17509103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li F; Fu T; Tong WD; Liu BH; Li CX; Gao Y; Wu JS; Wang XF; Zhang AP
    Mayo Clin Proc; 2016 Apr; 91(4):456-68. PubMed ID: 27046523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.